RETROVIR CAPSULE 250 mg

Land: Singapur

Sprache: Englisch

Quelle: HSA (Health Sciences Authority)

Wirkstoff:

ZIDOVUDINE

Verfügbar ab:

GLAXOSMITHKLINE PTE LTD

ATC-Code:

J05AF01

Dosierung:

250 mg

Darreichungsform:

CAPSULE

Verabreichungsweg:

ORAL

Verschreibungstyp:

Prescription Only

Hergestellt von:

GLAXO WELLCOME OPERATIONS

Berechtigungsdatum:

1993-08-06

Gebrauchsinformation

1 

 RETROVIR™  
ZIDOVUDINE 

QUALITATIVE AND QUANTITATIVE COMPOSITION 
_RETROVIR_ 100mg Capsules 
Hard gelatin capsules with opaque white cap and body and a central
dark-blue band, printed 
“Wellcome”, “100” and coded Y9C and each containing 100mg
Zidovudine.  
_RETROVIR_ 250mg Capsules  
Hard gelatin capsules with opaque blue cap, opaque white body and a
central dark-blue band, 
printed “Wellcome”, “250” and coded H2F and each containing
250mg Zidovudine.  
_RETROVIR_ Oral Solution  
Oral solution containing 50 mg zidovudine per 5 ml. It is clear,
pale yellow, and strawberry-
flavoured. Contains sodium benzoate. 
PHARMACEUTICAL FORM 
Hard capsules. 
Oral solution. 
CLINICAL PARTICULARS 
INDICATIONS  
_RETROVIR_ is indicated in combination with other anti-retroviral
agents for the treatment of 
Human Immunodeficiency Virus (HIV) infection in adults and children.

DOSAGE AND ADMINISTRATION 
_RETROVIR_ therapy should be initiated by a physician experienced in
the management of HIV 
infection. 
  DOSAGE IN ADULTS 
Although a broad range of dosages has been employed, 500 or 600mg/day
in three to five 
divided doses is commonly used worldwide. Alternatively 1000mg/day
in two (or four) divided 
doses is effective. The effectiveness of the lower dosages in the
treatment or prevention of HIV-
associated neurological dysfunction and malignancies is unknown.  
  DOSAGE IN CHILDREN 
2 

In children over the age of 3 months, the recommended starting dosage
is 180mg/m
2
 body 
surface area every 6 hours (720mg/m
2
/day). The maximum dosage should not exceed 200mg 
every 6 hours. The optimum dosage regimen remains to be determined
and may vary from 
patient to patient. A range of dosages, generally between 120 and
180mg/m
2 
body surface area 
every 6 hours (between 480 and 720mg/m
2
/day), has been used. The effectiveness of lower 
dosages in the treatment or
prevention of HIV-associated neurological dysfunction and 
malignancies i